Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke
Cidara und Otonomy: Weitere NBC-Favoriten knallen durch die Decke

Aktien von Cidara Therapeutics (WKN: A14R2R) und Otonomy (WKN: A119VZ) gehörten vergangene Woche mal wieder zu den Gewinnern im Biotech-Sektor. Stehen hier ähnliche Entwicklungen an wie jüngst bei

LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix

LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.

Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen

Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.

Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet

Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen
Qiagen: Übernahme geplatzt – so kann es jetzt weitergehen

Qiagen-Aktien (WKN: A2DKCH) verbilligen sich heute um -18,93% auf 30,02 Euro. Der Grund sind gescheiterte Übernahmegespräche.

Die Gespräche mit möglichen Übernahme-Interessenten würden nun beendet

Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference


Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak

Illumina to Webcast Upcoming Investor Conference Presentation
Illumina to Webcast Upcoming Investor Conference Presentation


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.



J.P. Morgan Healthcare

Illumina to Webcast Upcoming Investor Conference Presentation
Illumina to Webcast Upcoming Investor Conference Presentation


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.



J.P. Morgan Healthcare

Illumina to Webcast Upcoming Investor Conference Presentation
Illumina to Webcast Upcoming Investor Conference Presentation


Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invite investors to participate via webcast.



J.P. Morgan Healthcare

Intra-Cellular Therapies: Nächster Volltreffer von BB Biotech!
Intra-Cellular Therapies: Nächster Volltreffer von BB Biotech!

Bereits vor wenigen Tagen hatte ich hier bei sharedeals.de über die Forschungserfolge sowie dem damit verbundenen Kurssprung in der Aktie von Myovant Sciences berichtet. Heute nun hat die Schweizer

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment


Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is

Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million
Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million


Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an

Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

 Agilent Technologies to Present at J.P. Morgan Healthcare Conference
 Agilent Technologies to Present at J.P. Morgan Healthcare Conference


Agilent Technologies Inc. (NYSE: A) today announced the following presentation will be webcast for the investor community:



What: 38th Annual J.P. Morgan Healthcare Conference



Where: The Westin

EOS imaging Announces Its Financial Agenda For 2020
EOS imaging Announces Its Financial Agenda For 2020


Regulatory News:



EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and

Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302
Lysogene Announces the Publication of an Article in the Scientific Journal "Molecular Therapy Methods & Clinical Development” Demonstrating the Potential of Its Drug Candidate LYS-SAF302


Regulatory News:



Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today

Transgene Announces Financial Calendar for 2020
Transgene Announces Financial Calendar for 2020


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG) today announced its financial reporting dates for 2020:



March 11, 2020: 2019 Fiscal Year Results



May 6, 2020: First Quarter 2020

U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy


Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application (sNDA) for

U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy


Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application (sNDA) for

Pfizer and Mylan Announce Two Future Viatris Board Members
Pfizer and Mylan Announce Two Future Viatris Board Members


Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V

Pfizer and Mylan Announce Two Future Viatris Board Members
Pfizer and Mylan Announce Two Future Viatris Board Members


Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V

Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

Evotec: Neuer Sanofi-Deal in trockenen Tüchern
Evotec: Neuer Sanofi-Deal in trockenen Tüchern

Wie heute bekannt gegeben, erweitert Evotec (WKN: 566480) seine Service-Partnerschaft mit Sanofi. Die Aktie dreht nach anfänglichen Käufen ins Minus.

Bisher wurden pulverförmige Substanzen von

Humana Announces Atlanta, Charlotte and Houston as its Latest Bold Goal Communities
Humana Announces Atlanta, Charlotte and Houston as its Latest Bold Goal Communities


As part of the company’s efforts to improve the health and well-being of the communities it serves, Humana announced today that Atlanta, Charlotte and Houston are now Bold Goal communities

Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts
Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 28, 2020. The

Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts
Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 28, 2020. The